{"id":6968,"date":"2014-04-02T15:57:22","date_gmt":"2014-04-02T15:57:22","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/"},"modified":"2014-04-02T15:57:22","modified_gmt":"2014-04-02T15:57:22","slug":"nicox-resultats-financiers-2013-et-actualite-de-la-societe","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/","title":{"rendered":"Nicox : R\u00e9sultats Financiers 2013 et Actualit\u00e9 de la Soci\u00e9t\u00e9"},"content":{"rendered":"<blockquote>\n<p><strong>Michele Garufi, Pr\u00e9sident Directeur G\u00e9n\u00e9ral de Nicox<\/strong>, a d\u00e9clar\u00e9\u00a0: \u00ab\u00a0<em>Entre 2013 et d\u00e9but 2014, nous avons r\u00e9alis\u00e9 des progr\u00e8s significatifs et tangibles dans notre strat\u00e9gie visant \u00e0 \u00e9tablir Nicox en tant que soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie.\u00a0Nous avons mis en place notre organisation commerciale aux Etats-Unis et dans quatre des cinq principaux march\u00e9s europ\u00e9ens, en attirant des dirigeants commerciaux et des \u00e9quipes de vente fortement exp\u00e9riment\u00e9s. Nous avons \u00e9galement d\u00e9velopp\u00e9 notre pr\u00e9sence \u00e0 l\u2019international au travers d\u2019accords de distribution avec des partenaires de qualit\u00e9 dans d\u2019autres march\u00e9s clefs. De plus, l\u2019acquisition d\u2019Eupharmed a renforc\u00e9 notre pr\u00e9sence en Italie, l\u2019un des principaux march\u00e9s europ\u00e9ens pour l\u2019ophtalmologie.\u00a0<\/em><\/p>\n<p><em>Pour compl\u00e9ter cette organisation, nous constituons rapidement un portefeuille diversifi\u00e9 de produits ophtalmiques, dont notre propre gamme de lubrifiants pour la s\u00e9cheresse oculaire, lanc\u00e9e r\u00e9cemment en Europe sous la marque Xailin\u2122. Notre portefeuille innovant nous donne acc\u00e8s \u00e0 plusieurs domaines th\u00e9rapeutiques parmi les plus importants en ophtalmologie\u00a0: RetnaGene\u2122 AMD est le test le plus avanc\u00e9 pour \u00e9valuer le risque de progression de la DMLA, une pathologie qui touche environ 15 millions d\u2019am\u00e9ricains<sup>1<\/sup>\u00a0; Sj\u00f6\u2122 est le premier test sp\u00e9cifique pour l\u2019identification pr\u00e9coce du syndrome de Gougerot-Sj\u00f6gren, une maladie auto-immune grave et sous-\u00e9valu\u00e9e\u00a0; et AdenoPlus<sup>\u00ae<\/sup> facilite le diagnostic diff\u00e9rentiel de la conjonctivite aig\u00fce. Le programme de Phase 3 de notre compos\u00e9 brevet\u00e9, le latanoprost\u00e8ne bunod, continue de progresser avec notre partenaire Bausch + Lomb. On estime que le march\u00e9 du glaucome pourrait d\u00e9passer les $3 milliards d\u2019ici 2015<sup>2<\/sup> et le latanoprost\u00e8ne bunod est le seul compos\u00e9 ayant montr\u00e9 des r\u00e9sultats sup\u00e9rieurs au Xalatan<sup>\u00ae<\/sup> dans une \u00e9tude de Phase 2b solide.\u00a0\u00bb<\/em><\/p>\n<\/blockquote>\n<blockquote>\n<p><strong>Evelyne Nguyen, Directeur Administratif et Financier de Nicox<\/strong>, a comment\u00e9 : \u00ab <em>En 2013, Nicox s\u2019est concentr\u00e9 sur la mise en place de son r\u00e9seau commercial, aux Etats-Unis et dans les cinq principaux march\u00e9s Europ\u00e9ens. Par ailleurs, la soci\u00e9t\u00e9 a continu\u00e9 \u00e0 rechercher de nouveaux produits ophtalmiques au travers d\u2019accords de partenariats et d\u2019acquisitions. Il en est r\u00e9sult\u00e9 l\u2019acquisition d\u2019Eupharmed en Italie et la prise de licence du test RetnaGene\u2122 AMD aupr\u00e8s de Sequenom, permettant au Groupe d\u2019acc\u00e9der \u00e0 la fois \u00e0 de nouveaux march\u00e9s et de nouveau produits innovants. L\u2019acquisition d\u2019Eupharmed a \u00e9t\u00e9 r\u00e9alis\u00e9e par \u00e9mission d\u2019actions nouvelles, ce qui d\u00e9montre la confiance de notre partenaire en la capacit\u00e9 commerciale de Nicox et nous permet de construire de la valeur avec une consommation optimale de nos ressources financi\u00e8res.\u00a0<\/em><\/p>\n<p><em>Au 31 d\u00e9cembre 2013, la Soci\u00e9t\u00e9 disposait d\u2019une tr\u00e9sorerie, d\u2019\u00e9quivalents de tr\u00e9sorerie et d\u2019instruments financiers courants et non courants de plus de \u20ac58\u00a0millions, ce qui nous donne les moyens en 2014 de conduire nos activit\u00e9s commerciales et de continuer \u00e0 investir dans notre infrastructure marketing de mani\u00e8re significative.\u00a0En 2014, nous comptons sur l\u2019apport sur un exercice complet des contributions des produits mis sur le march\u00e9 ou acquis r\u00e9cemment, notamment de la gamme Eupharmed.\u00a0<\/em>\u00bb<\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>R\u00e9sultats financiers pour l\u2019ann\u00e9e 2013 et  vue d\u2019ensemble des activit\u00e9s<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-6968","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : R\u00e9sultats Financiers 2013 et Actualit\u00e9 de la Soci\u00e9t\u00e9 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : R\u00e9sultats Financiers 2013 et Actualit\u00e9 de la Soci\u00e9t\u00e9 - Nicox\" \/>\n<meta property=\"og:description\" content=\"R\u00e9sultats financiers pour l\u2019ann\u00e9e 2013 et vue d\u2019ensemble des activit\u00e9s\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2014-04-02T15:57:22+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : R\u00e9sultats Financiers 2013 et Actualit\u00e9 de la Soci\u00e9t\u00e9\",\"datePublished\":\"2014-04-02T15:57:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\\\/\"},\"wordCount\":538,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\\\/\",\"name\":\"Nicox : R\u00e9sultats Financiers 2013 et Actualit\u00e9 de la Soci\u00e9t\u00e9 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2014-04-02T15:57:22+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : R\u00e9sultats Financiers 2013 et Actualit\u00e9 de la Soci\u00e9t\u00e9 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : R\u00e9sultats Financiers 2013 et Actualit\u00e9 de la Soci\u00e9t\u00e9 - Nicox","og_description":"R\u00e9sultats financiers pour l\u2019ann\u00e9e 2013 et vue d\u2019ensemble des activit\u00e9s","og_url":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/","og_site_name":"Nicox","article_published_time":"2014-04-02T15:57:22+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/"},"author":{"name":"","@id":""},"headline":"Nicox : R\u00e9sultats Financiers 2013 et Actualit\u00e9 de la Soci\u00e9t\u00e9","datePublished":"2014-04-02T15:57:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/"},"wordCount":538,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/","url":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/","name":"Nicox : R\u00e9sultats Financiers 2013 et Actualit\u00e9 de la Soci\u00e9t\u00e9 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2014-04-02T15:57:22+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-2013-et-actualite-de-la-societe\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=6968"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6968\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=6968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=6968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=6968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}